Reversal of drug-induced anticoagulation: Old solutions and new problems

Transfusion

Volumn 52, Issue SUPPL. 1, 2012, Pages

  Dzik, Walter Sunny ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; COAGULATING AGENT; COFACT; COUMARIN; DABIGATRAN; FRESH FROZEN PLASMA; PROFILINE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; RIVAROXABAN; S TIM 4; UMAN DI; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; DRUG ANTAGONISM; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; HUMAN; NONHUMAN; PRESCRIPTION;

ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; BLOOD COMPONENT TRANSFUSION; HEMATOLOGY; HEMORRHAGE; HUMANS; MODELS, BIOLOGICAL; PLASMA; VITAMIN K; WARFARIN;

EID: 84861173947     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03690.x     Document Type: Article

References (42)

1. Goodnough LT, Shander A,. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood 2011; 117: 6091-9.
2. Bauer KA,. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 2011; 9 Suppl 1: 12-9.
3. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE, Altman RB,. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011; 90: 625-9.
4. Raj G, Kumar R, McKinney WP,. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 1999; 159: 2721-4.
5. Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C, Venco A, Ageno W,. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002; 137: 251-4.
6. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D,. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003; 163: 2469-73.
7. Fiore LD, Scola MA, Cantillon CE, Brophy MT,. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001; 11: 175-83.
8. Roback JD, Grossman BJ, Harris T, Hillyer CD, editors. Technical manual. 17th ed. Bethesda (MD): American Association of Blood Banks; 2011. p. 275.
9. Goldstein JN, Thomas SH, Frontiero V, Joseph A, Engel C, Snider R, Smith EE, Greenberg SM, Rosand J,. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006; 37: 151-5.
10. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH,; American College of Chest Physicians. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 Suppl: e152S-84S.
11. Kalina U, Bickhard H, Schulte S,. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract 2008; 62: 1614-22.
12. Patanwala AE, Acquisto NM, Erstad BL,. Prothrombin complex concentrate for critical bleeding. Ann Pharmacother 2011; 45: 990-9.
13. Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R,. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009; 49: 1171-7.
14. Imberti D, Barillari G, Biasioli C, Bianchi M, Contino L, Duce R, D'Incà M, Gnani MC, Mari E, Ageno W,. Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. Blood Transfus 2011; 9: 148-55.
15. Makris M, Van Veen JJ,. Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal? Blood Transfus 2011; 9: 117-9.
16. Sarode R, Matevosyan K, Bhagat R, Rutherford C, Madden C, Beshay JE,. Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage. J Neurosurg 2012; 116: 491-7.
17. Li G, Rachmale S, Kojicic M, Shahjehan K, Malinchoc M, Kor DJ, Gajic O,. Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients. Transfusion 2011; 51: 338-43.
18. Boulis NM, Bobek MP, Schmaier A, Hoff JT,. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 45: 1113-8; discussion 1118-9.
19. Dentali F, Marchesi C, Pierfranceschi MG, Crowther M, Garcia D, Hylek E, Witt DM, Clark NP, Squizzato A, Imberti D, Ageno W,. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011; 106: 429-38.
20. Fredriksson K, Norrving B, Stromblad LG,. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992; 23: 972-7.
21. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF,. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 477-80.
22. Cartmill M, Dolan G, Byrne JL, Byrne PO,. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14: 458-61.
23. Demeyere R, Gillardin S, Arnout J, Strengers PF,. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 2010; 99: 251-60.
24. Dickneite G,. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res 2007; 119: 643-51.
25. Illanes S, Zhou W, Schwarting S, Heiland S, Veltkamp R,. Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. Stroke 2011; 42: 191-5.
26. Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME,. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood 2010; 116: 693-701.
27. Wojcik C, Schymik ML, Cure EG,. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med 2009; 2: 217-25.
28. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L,; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
29. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Wallentin L, et al,.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
30. Harper PY, Merriman E,. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366: 864-6.
31. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M,. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-9.
32. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, Heiland S, van Ryn J, Veltkamp R,. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-9.
33. Tinel HH, Perzborn E,. Recombinant factor VIIA partially reverses the anticoagulant effect of high-dose rivaroxaban - a novel, oral, direct factor XA inhibitor - in rats [abstract]. J Thromb Haemost 2007; 5 Suppl 2: P-W-652.
34. van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W,. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran by recombinant factor VIIa or activated prothrombin complex concentrate [abstract]. Haematologica 2008; 93 Suppl 1: 148.
35. van Ryn J, Schurer J, Kink-Eiband M, Clemens A,. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation [abstract]. Blood 2011; 118: 2316.
36. Gruber A, Marzec U, Buetehorn U, Hanson S, Perzborn E,. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates [abstract]. Blood 2008; 112: 3825.
37. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW,. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119: 2172-4.
38. Garber ST, Sivakumar W, Schmidt RH,. Neurosurgical complications of direct thrombin inhibitors-catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg 2012 Mar 6. [Epub ahead of print]
39. Harper P, Young L, Merriman E,. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366: 864-6.
40. van Ryn J, Sieger P, Kink-Eiband M, Gansser D, Clemens A,. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro [abstract]. Blood 2009; 114: 1065.
41. Stangier J, Rathgen K, Stahle H, Mazur D,. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-68.
42. Lu G, DeGuzman F, Lakhotia S, Hollenbach SJ, Phillips DR, Sinha U,. Recombinant antidote for reversal of anticoagulation by Factor Xa inhibitors [abstract]. Blood 2008; 112: 983.